In addition, an immune high-risk signature characterized by high tumor-associated neutrophils (TANs), high FOXp3+, and low CD8+ T cells was recently reported to be significantly associated with poor disease-free and overall survival rates (DFS and OS) and resistance to gemcitabine treatment after recurrence in eCCA patients5. Here, CD8A is linked to neoplasm.